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Abstract Long-term effects of the growing population of HIV-treated people in Southern Africa
on individuals and the public health sector at large are not yet understood. This study proposes a
novel ‘ratio’ model that relates CD4+ T-cell counts of HIV-infected individuals to the CD4+ count
reference values from healthy populations. We use mixed-effects regression to fit the model to
data from 1616 children (median age 4.3 years at ART initiation) and 14,542 adults (median age 36
years at ART initiation). We found that the scaled carrying capacity, maximum CD4+ count relative
to an HIV-negative individual of similar age, and baseline scaled CD4+ counts were closer to
healthy values in children than in adults. Post-ART initiation, CD4+ growth rate was inversely
correlated with baseline CD4+ T-cell counts, and consequently higher in adults than children. Our
results highlight the impacts of age on dynamics of the immune system of healthy and HIV-infected
individuals.
Introduction
The efficacy with which antiretroviral therapy (ART) suppresses HIV viral load and restores lympho-
cyte responses to pathogen-derived antigens, normally lost due to viral replication, is
well established (Cooney, 2002; Autran et al., 1997). Following ART initiation, for the majority of
HIV-infected individuals, the CD4+ T-cell counts rapidly increase for approximately 4–6 months
(Lawn et al., 2006), followed by a slower increase in the next 2–4 years, after which cell numbers
plateau (Pinzone et al., 2012). Despite the successes of ART, several studies have demonstrated
that large proportions of patients experience incomplete immune restoration following treatment
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initiation. In Sub-Saharan Africa, approximately 10–16% of children on ART (Mutwa et al., 2014)
and variable proportions of adults (Barth et al., 2011; Fatti et al., 2014; Mee et al., 2008) fail to
suppress viral load within 12 months of ART initiation. Further, among those that do suppress viral
load, many are suboptimal immunological responders (35–40%), that is, they do not reach a CD4+
T-cell count greater than 500 cells/mL within 5 years (Nakanjako, 2016; Swiss HIV Cohort Study
et al., 2005). Some patients demonstrate no improvement at all (Lawn et al., 2006).
A variety of statistical methods have been used to model the recovery of CD4+ T-cell counts after
ART initiation. A prior review of sub-Saharan African studies of this type established that generalized
linear mixed models and generalized estimating equations were most commonly used
(Sempa et al., 2017). However, such models are not ‘mechanistic’, in the sense that they make no
assumptions regarding the underlying biological processes involved in CD4+ T-cell reconstitution.
For this reason, these methods do not allow inferences regarding the dynamics of CD4+ recovery.
Recent studies have employed an asymptotic ‘semi-mechanistic’ mixed model to describe CD4+
count recovery in children (Lewis et al., 2012; ARROW Trial Team et al., 2013; Lewis et al., 2017;
De Beaudrap et al., 2008) and adults (ANRS 1215/90 Study Group et al., 2009; Means et al.,
2016). These models simply assume that CD4+ T-cell counts follow an asymptotic recovery process
in all patients. However, it has been demonstrated that in patients with suboptimal or no immune
recovery, response trajectories do not follow this profile (ARROW Trial Team et al., 2013). Compli-
cating this picture, diverse CD4+ T-cell count variable transformations were applied, different demo-
graphic groups were studied and there is large natural variability of such cell counts across different
population groups (Schaberg et al., 1997; Abuye et al., 2005; Maini et al., 1996). As a result,
these models do not allow for comparisons across heterogeneous groups of individuals.
In this study, we present a novel mechanistic model that describes the dynamics of CD4+ T-cell
count responses in HIV-infected individuals relative to those of healthy individuals. We use nonlinear
eLife digest The human immunodeficiency virus (HIV) remains an ongoing global pandemic.
There is currently no cure for HIV, but antiretroviral therapies can keep the virus in check and allow
individuals with HIV to live longer, healthier lives. These drugs work in two ways. They block the
ability of the virus to multiply and they allow numbers of an important type of infection-fighting cell
called CD4+ T cells to rebound.
As more patients with HIV survive and transition from one life stage to the next, it is critical to
understand how long-term antiretroviral therapies will affect normal age-related changes in their
immune systems. The health of an immune system can be evaluated by looking at the number of
CD4+ T cells an individual has, though this will vary by age and location. Clinicians use the same
metrics to assess the immune health of individuals with HIV, however, as they age, it becomes a
challenge to identify if a patient’s immune system recovers normally or insufficiently. Thus, learning
more about age-related differences in CD4+ T cells in people living with HIV may help improve their
care.
Using data from 1,616 children and 14,542 adults from South Africa, Ujeneza et al. created a
simple mathematical model that can compare the immune system of person with HIV with the
immune system of a similarly aged healthy individual. The model shows that among individuals with
HIV receiving antiretroviral therapies, children have CD4+ T-cell numbers that are closest to the
numbers seen in healthy individuals of the same age. This suggests that children may be more able
to recover immune system function than adults after beginning treatment. Children also start
antiretroviral therapies before their immune system has been severely damaged, while adults tend
to start treatment much later when they have fewer CD4+ T cells left.
Ujeneza et al. show that the fewer CD4+ T cells a person has when they start treatment, the
faster the number of these cells grows after starting treatment. This suggests that the more
damaged the immune system is, the harder it works to recover. This reinforces the need to identify
people infected with HIV as soon as possible through testing and to begin treatment promptly. The
new model may help clinicians and policy makers develop screening and treatment protocols
tailored to the specific needs of children and adults living with HIV.
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mixed modelling methods and data from large cohorts of adults and children in South Africa. We
assess the generalizability of this model from children to adults. We compare it to the previously
published asymptotic model and investigate the impact of demographic and clinical characteristics
on long-term immune outcomes.
Methodology
ART patient data
De-identified longitudinal data from HIV-infected patients receiving ART in 13 South African cohorts
was provided by the International Epidemiologic Databases to Evaluate AIDS in Southern Africa
(IeDEA-SA) (https://www.iedea-sa.org/) (ART-LINC Collaboration of IeDEA et al., 2008; IeDEA and
COHERE Cohort Collaborations and Anderegg, 2018). The initial data set was composed of
2,858,743 CD4+ count observations for 223,688 patients of whom 202,108 were adults, 21,267 were
children and 313 had no recorded date of birth or date of ART initiation. Children were defined as
those aged 17 or younger at treatment initiation. After removing observations that were unrealistic
(outside plausible biological ranges) or missing date of measurement, 189,647 adults and 19,060
children remained (Figure 1).
‘Ratio’ model construction
The ratio model relates the CD4+ T-cell dynamics from HIV+ individuals to those of healthy individu-
als. We first defined, then merged, separate models for each group, using the logistic growth
model. This model assumes that a given quantity grows exponentially until it approaches a constant
carrying capacity k (Figure 2), or limit, to represent the dynamics of the immune system. This con-
cept has been used in prior studies to describe the proliferation rate of CD4+ T-cells for individuals
on therapy (Kaufmann et al., 2001; Di Mascio et al., 2006). We denote the CD4+ T-cell count
‘growth’ (or regeneration) rate of an individual on ART by r, and the ‘environmental’ (or physiologi-
cal) carrying capacity by k, which can be thought of as the maximal number of CD4+ T-cells that can
be sustained by all available biological resources.
For HIV-infected people, the rate of change of CD4+ T-cells x; per L per unit time, t; is








where t starts at ART initiation. The theoretical growth rate r is actually an effective rate, a constant
obtained by taking the average of the growth rate at different time points. This ‘instant’ growth rate
increases for values of x smaller than the inflexion point k=2 and starts decreasing thereafter, as the
value of x approaches the carrying capacity k.
The solution to Equation 1 gives the expression for CD4+ T-cell counts per L at time t as:






where x0 is the CD4+ T-cell count of the individual, at ART initiation.
A study on healthy South African population showed that their CD4+ counts increased from
young adulthood until about 70 years of age (Malaza et al., 2013). Thus, we can also describe the
CD4+ T-cell counts in a healthy individual y tð Þ at time t, as:






where s is the CD4+ T-cell growth rate, q the carrying capacity, and time t has an origin equivalent
to ART initiation in an age-matched HIV infected patient. Thus, the equation describes the immune
system dynamics of the healthy individual, starting from when they have a similar age as their corre-
sponding HIV-infected counterpart.




; K ¼ k
x0
, and Q ¼ q
y0
, and simplifying to obtain, z tð Þ, the scaled CD4+ T-cell count at time t:
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189,647eligible adults with 
realistic measurement 
12,238 adults with at least 
five CD4+ T-cells 
measurements 
14,542 adults included in the 
final analysis 
1,616 children included in the 
final analysis 
 
19,060 eligible children with 
realistic measurement 
1,312 children with at least 




· patients with less than four 
CD4+ T-cells measurements  
· patients with incomplete data 
for covariates of interest 
 
223,688 HIV-infected patients on ART 
Excluded patients with 
no valid dates of birth, 
date of ART initiation or 
date of lab measurement 
223,375 eligible patients 
Excluded patients with 
no valid observations 
Figure 1. Data chart explaining the exclusion and inclusion criteria.
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z tð Þ ¼ z0
K
Q
1þ e st Q  1ð Þ
1þ e rt K  1ð Þ
; (4)
where K and Q are the CD4+ T-cell scaled carrying capacities of an HIV-infected and a healthy age-
matched individual, respectively; and z0 the ratio of the baseline CD4+ T-cell count of the HIV-
infected individuals to that of the healthy individual, in order words, the baseline scaled CD4+ T-cell
counts. An implication of this model is that when the value of K is close to unity, the patient’s long-
term carrying capacity is approaching the particular patient’s ‘homeostatic optimum’ for CD4+ T-cell
counts, that is, the amount of CD4 cells that can be sustained by the available biological resources.
In this case a subsequent increase in CD4+ T-cell counts would be unlikely. Further, associated with
an ‘immune set-point’ achieved in healthy adults their value of Q would tend to unity. In healthy chil-
dren, this is not so owing to growth, that is, their CD4+ T-cell count changes with the increase of
their total blood volume (Bains et al., 2009). Thus, their value of Q is expected to be less than one.
Additionally, a baseline scaled CD4+ T-cell count of 1 means that the individual started therapy
with a normal CD4+ T-cell count for their age, while a value smaller than one indicates that an indi-
vidual started therapy with a lower CD4+ count compared with those of healthy individuals of the
same age. Note that both growth rates for HIV-infected and healthy individuals are the same
(unchanged), from the original logistic growth models to the ‘ratio’ model. A table indicating the
ranges for each parameter is available in Supplementary file 1.
Figure 2. Plot of the logistic growth model. The dotted red line represents that carrying capacity k, while the dotted blue line is at the inflexion point k/
2.
The online version of this article includes the following source data for figure 2:
Source data 1. Data source to reproduce the plot for the logistic growth model.
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Model fitting techniques
We used nonlinear mixed effects techniques (NLMM) to fit all models to data. NLMMs are character-
ized by two main components: a fixed effect part that describes the population mean, and the ran-
dom effects that describe individual subjects’ deviations from the mean. If we denote by  the
vector of population estimates, and by bi the matrix of the random effects’ estimates, a general
mathematical description of NLMM for continuous variables is given by,
zi;j ¼ f ðpi;j; ;biÞþ gðpi;j; ;bi;gÞi;j;1 iN;1 j ni; (5)
where zi;j is the scaled CD4+ T-cell counts of patient i at time j; function f is the nonlinear model of
interest and g is the structure of the error model; N is the total number of subjects and ni the num-
ber of observations j for each subject i. Both f and g depend on the predictor variables pi;j, the pop-
ulation parameters , and the random effects bi. In addition, the function g depends on the form
chosen for the error model, which is governed by a set of parameters g: In this study, we used a pro-
portional error model, such that g¼ df and g¼ d (single constant parameter d), and Equation 4 as




1þ Qi   1ð Þe
 siti;j
1þ Ki  1ð Þe riti;j
ð1þ di;jÞ;1 iN;0 j ni: (6)
For purposes of comparison, we also applied the same NLMM methodology to an ‘asymptotic’
model, similar to that previously described (Lewis et al., 2012), such that,
zi;j ¼ Asymi  Asymi  R0ið Þe
citi;jð Þ 1þ d"i;j
  
; 1 i N; 0  j  ni; (7)
where Asymi is the value of the asymptote for patient i, R0i their intercept, and ci their logarithm of
rate of increase of scaled CD4+ T-cell counts. The term Asymi  R0ið Þ represents the scaled increase
of CD4+ T-cells following ART initiation.
The NLMM method assumes that the random effects are normally distributed, with mean zero
and variance-covariance matrix W: bi ~ @ 0;Wð Þ; and the errors "i;j are also normally distributed with
mean zero and variance 1: "i;j ~ @ 0; 1ð Þ. These represent noise and errors in the data. The individual
parameters (denoted by a matrix  i) are given by  i ¼  Ci þ bi , with Ci the matrix of individual
covariates. A demo code is available through a github repository (https://github.com/EvaLiliane/
RM_Code_eLife [copy archived at swh:1:rev:624ff31c5fc969885f29b7291ee06886d24c64f7];
Ujeneza, 2020).
Variable scaling
The key outcome variable is scaled CD4+ T-cell count. In both infected adults and children, the cell
counts post-ART initiation were scaled by reference values from healthy populations, to obtain the
outcome variable.
For HIV-infected children these reference values were calculated from the cross-sectional data
(see description in Appendix 1) of healthy children at specific ages, due to the large variability in
CD4+ T-cell counts in the early years of life. For the reference values by age, a single exponential
model was fitted to the healthy children’s cross-sectional data and continuous population estimates
were simulated (see Appendix 1—table 1 and Appendix 1—Figure 1). These were within the nor-
mal CD4+ T-cell counts ranges published in South Africa (Lawrie et al., 2009; Lawrie et al., 2015)
and elsewhere (Idigbe et al., 2010; Pediatric AIDS Clinical Trials Group et al., 2003). We then
scaled all HIV-infected children’s CD4+ T-cell counts as follows:
zi;j að Þ ¼
xi;j að Þ
y að Þ
; 1 i N ; 0  j  ni; 0  a  203; (8)
where zi;j is the scaled CD4+ T-cell counts of patient i of age a (in months) at time j (measured as
time since ART initiation); xi;j is the CD4+ T-cell counts of an HIV-infected child i of age a and
y að Þ is the CD4+ T-cell counts of a healthy child of similar age a as patient i. Scaling CD4+ T-cell
counts of HIV-infected children by that of healthy children of similar ages enabled the comparison of
CD4+ T-cell counts responses across ages, while simultaneously accounting for the child’s growth
and immune system development.
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Table 1. Patient demographics.






Demographic Number of patients All 19,060 1312
Median age, years (IQR) All 4.4 (1.1,8.8) 4.5 (1.4,7.9)
Baseline WHO stage
(% relative to all)
Stage I 693 (3.6%) 31 (2.3%)
















Median time on ART, years (IQR) All 2.0 (0.0,4.0) 4.0 (3.0,5.0)
Year of ART initiation (IQR) 2004–2012 2004–2012
Clinical
characteristics
CD4+ T-cell count at baseline, count/mL (IQR) 493
(229,890)
404 (159,706)
Median scaled CD4+ T-cell count at baseline, (IQR) 0.30
(0.15,1.50)
0.24 (0.09,0.42)
Median viral load at baseline, per 1000 copies/mL (IQR) 150
(20,7342)
155 (29,670)
Median log viral load at baseline, copies/mL (IQR) 5.1 (4.3,6.8) 5.1 (4.4,5.8)











Demographic Number of patients All 189,647 12,238
Median age, years (IQR) All 35 (29,42) 36 (30.6,42.9)
Baseline WHO stage

















Median time on ART, years (IQR) All 1.0 (0.0,3.0) 3.0 (2.0,5.0)
Year of ART Initiation IQR 2004–2012 2004–2012
Table 1 continued on next page
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For adults, normal reference values were estimated using values obtained from the literature
(Malaza et al., 2013; Lawrie et al., 2009, Ngowi et al., 2009; Lugada et al., 2004; Institute of
Human Virology/Plateau State Specialist Hospital AIDS Prevention in Nigeria Study Team et al.,
2005; Oladepo et al., 2009) (see details in Appendix 1—table 2 and Appendix 1—figure 2).
Although healthy adult CD4+ T-cell counts are known to vary with age, this variability is small com-
pared to that observed in children, with an average difference of 100 cells between 25 and 60 years
old healthy adults [Oladepo et al., 2009] vs 1500 cells difference between 3 months and 15 years
old healthy children [Lawrie et al., 2015]. Similarly, average CD4+ T-cell counts differences between
male and female adults in South Africa were in the range of 80–150 cells (Malaza et al., 2013;
Lawrie et al., 2009). We evaluated results obtained from scaling HIV-infected CD4+ counts by simu-
lated age and sex-dependent reference CD4+ counts values, and found minor or no difference with
those obtained from CD4+ T-cell counts scaled by a single value. We obtained exactly the same
population estimates and very similar individual parameter estimates. These were evaluated and we
found no significant differences (see Supplementary file 2). Thus, due to the unavailability of individ-
ual age-specific data for a South African healthy adult population, a single normal reference value,
that is, a constant y of 800 CD4+ T-cells per mL, was used to scale all CD4+ T-cell count observations




Baseline scaled CD4+ T-cell counts
Our analysis was restricted to patients with available baseline (i.e. at antiretroviral treatment initia-
tion) CD4+ T-cell counts and sufficient observations to estimate all model parameters (Figure 1). We
categorized as baseline any CD4+ count measurement that was taken within 15 days before or after
the ART initiation date. Two model-fitting scenarios were defined based on the availability of
enough observations to estimate the model parameters:
Table 1 continued







Median CD4+ T-cell count at baseline, count/mL (IQR) 140
(67,206)
128 (62,196)
Median scaled CD4+ T-cell count at baseline (IQR) 0.18
(0.08,0.26)
0.16 (0.07,0.24)
Median viral load at baseline, per 1000 copies/mL (IQR) 27
(0.8,132.3)
39 (2.3, 151)
Median log viral load at baseline, copies/mL (IQR) 4.4 (2.9,5.1) 4.5 (3.3,5.1)
Number of patients that suppressed viral load within 12 months of treatment initiation (%









Note: A z-score BMI of  1 indicates that the child’s body mass index is at one standard deviation below the body mass of a healthy child, while a z-score
BMI of 0 means that the child has normal body mass for his/her age.
Table 2. BIC comparison of the unadjusted ratio and asymptotic models, under different scenarios for baseline scaled CD4+ T-
cell counts z0.
Scenario 1: z0 estimated Scenario 2: z0 as a predictor
Ratio model Asymptotic model Ratio model Asymptotic model
Adults Sample size 12,238 14,542
BIC  134,016.7  126,716.2  178,702.3  186,244.2
Children Sample size 1312 1616
BIC  2,137.1  1,523.1  6,028.8  7,969.7
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Scenario 1: In which baseline scaled CD4+ T-cell counts were estimated, including 1312 children
and 12,238 adults, with a minimum of five CD4+ T-cell counts measurements and no missing values
for our variables of interest (specified below).
Scenario 2: Where baseline scaled CD4+ T-cell counts were used as a predictor, including 1616
children and 14,542 adults, with a minimum of four CD4+ T-cell counts measurements and no miss-
ing values for our variables of interest. These variables were CD4+ T-cell counts since ART initiation;
viral load, age and body mass index at ART initiation; sex and suppression (or not) of viral load
within 12 months of ART initiation.
In this paper we will mostly discuss results of scenario 1, where all parameters are estimated. The
methodology used and most of the obtained results are applicable for scenario 2, when baseline
CD4+ T-cells counts data are available. We also present results of scenario 2.
Structure of the random effects
Under both scenarios, in the initial model fitting, all parameters were assumed to vary per individual
(i.e. there were random effects on all parameters) and their distributions was set as log-normal.
Thus, for each parameter , the distribution of individual values was log ið Þ ~ @ ; !
2ð Þ, with mean
m and variance w2. Random effects were assumed to be independent and the identity diagonal
matrix was used for the variance–covariance structure.
This assumption was later relaxed and different variance–covariance structures were subsequently
evaluated. To compare models, the Akaike and Schwarz information criteria (AIC and BIC respec-
tively), computed by importance sampling, were used (see Comets et al., 2017). Models with a full
variance–covariance matrix were retained as this structure gave the lowest AIC and BIC values.
Covariates
Our choice of covariates was based on literature reviews (Pinzone et al., 2012; Sempa et al., 2017),
data availability, and biological plausibility. We considered baseline characteristics that were mea-
sured within 15 days before or after ART initiation, namely age, z-score body-mass-index (BMI, for
children), and viral load. Other covariates included sex and viral suppression (or not) within 12
months of ART initiation.
Patient age at ART initiation was expressed in months. Z-score BMI at baseline for children was
calculated using WHO-Igrowup’s package (WHO Multicentre Growth Reference Study Group,,
2006). ‘Suppress’, a binary, was defined as reaching an undetectable viral load (<1000 copies/mL) or
not, within 12 months of ART initiation. Baseline viral load was log transformed to simplify model fit-
ting. Baseline age and sex effects were included for all parameters, while viral load suppression,
baseline log viral load and BMI z-scores for children, were only included for the parameters describ-
ing the longitudinal immune responses of individuals on ART, namely: scaled carrying capacity post-
ART, CD4+ T-cell growth rate post-ART and baseline scaled CD4+ T-cell count .
Additional considerations
Final adjusted models were obtained using a backward–forward stepwise approach using p-value cri-
terion for covariate inclusion and AIC, BIC for the overall models. To evaluate the robustness of our
results, we compared the estimated parameters of the full analysis described above using only three
covariates: sex, baseline age, and baseline viral load, with those from models with all covariates.
All graphs and computations were produced in the statistical environment R (R Development
Core Team, 2017). Nonlinear mixed model fitting employed the saemix R package (Comets et al.,
2005), which uses a stochastic approximation, expectation-maximization algorithm for parameter
estimation. All final adult and children models (Figures 3 and 4) converged relatively rapidly towards
their estimated values, as shown by the log-likelihood graphs (Figure 3—figure supplement 1 and
Figure 4—figure supplement 1). Even when initial values were marginally varied, the final models
converged to similar estimates.
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Results
Clinical characteristics
Cohort characteristics are summarized in Table 1. For scenario 1, the median number of clinical visits
was 8, per patient, in both adults IQR (6,9) and children IQR (6,10), with a median follow-up time of
3 years for adults IQR (2,5) and 4 years for children IQR (3,5). At baseline, that is, ART initiation, the
median age for children was 4.5 years IQR (1.4, 7.9) and 36 years IQR (30.7, 43) for adults. A clinical
WHO stage III was most common in all patients at ART initiation. Among adults, there were more
females than males (56.7% versus 43.2% respectively), but only slightly more females among children
(51.3% versus 48.6% males). All patients in our data sets initiated therapy between 1997 and 2013,
with 95% of them initiating in the period, 2003–2012. About 53.4% of children reached a CD4+
Figure 3. Children population-level CD4 trajectory, as estimated by the unadjusted ratio and asymptotic models, and the adjusted ratio model.
Simulation of population-level CD4+ count trajectory for children, from unadjusted fixed estimates of the asymptotic model (AM) in blue and the ratio
model (RM) in green. The red line represents simulation from the adjusted population-level RM estimates. Parameters used for the AM are presented in
Supplementary file 3 – Table 1, scenario 1. Those used for the RM are estimated fixed effect for the null model (not shown in the paper): K = 3.4,
Q = 0.9, r = 0.35, s = 0.017, z0 = 0.18. Fixed effect presented in Table 3 (scenario 1) are used for the adjusted ratio model (Adj RM), for baseline
covariates z-score BMI, age, log viral load; and sex and suppression of viral load within 12 months of starting therapy. Convergence plots for the Adj
RM are given in Figure 3—figure supplement 1, and simulation of individual fits in Figure 3—figure supplement 2.
The online version of this article includes the following source data and figure supplement(s) for figure 3:
Source data 1. Data source to reproduce the population-level CD4 trajectories plot for children.
Figure supplement 1. Convergence plots for children adjusted ratio model.
Figure supplement 2. Sample of individual children plots for the adjusted ratio model.
Figure supplement 2—source data 1. Data source to reproduce the individual-level CD4 trajectories plot for children.
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T-cell count of 500 per mL within 12 months of ART initiation, while only 4.4% of adults reached the
same threshold. This number increases to 10.1% after 2 years of therapy for adults.
The median baseline CD4+ T-cell counts for children and adults were low at 404 per mL IQR
(159.7,706.2) and 128 per mL IQR (62,196) respectively (Table 1). Higher counts at ART initiation
were more common in younger (0–5 year’s age group) versus older children (>5 years). In adults, no
differences were found in CD4+ T-cell counts at baseline, for different age groups. Both children
and adults that presented with higher counts at baseline had lower viral loads versus those with low
baseline counts.
Figure 4. Adults population-level CD4 trajectory, as estimated by the unadjusted ratio and asymptotic models, and the adjusted ratio model.
Simulation of population-level CD4+ count trajectory for adults, from unadjusted fixed estimates of the asymptotic model (AM) in blue, and the ratio
model (RM) in green. The red line represents simulation from the adjusted population-level RM estimates. Parameters used for the AM are presented in
Supplementary file 3 – Table 1, scenario 1. Those used for the RM are estimated fixed effect for the null model (not shown in the paper): K = 2.54,
Q = 0.38, r = 1.23, s = 0.01, z0 = 0.13. Fixed effect presented in Table 3 (scenario 1) are used for the adjusted ratio model (Adj RM), for baseline
covariates sex, age, log viral load, and suppression of viral load within 12 months of starting therapy. Convergence plots for the Adj RM are given in
Figure 4—figure supplement 1, and simulation of individual fits in Figure 4—figure supplement 2.
The online version of this article includes the following source data and figure supplement(s) for figure 4:
Source data 1. Data source to reproduce the population-level CD4 trajectories plot for adults.
Figure supplement 1. Convergence plots for adults adjusted ratio model.
Figure supplement 2. Sample of individual adult plots for the adjusted ratio model.
Figure supplement 2—source data 1. Data source to reproduce the individual—level CD4 trajectories plot for adults.
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Comparison of models and random effects structures
The performance of both asymptotic and ratio models, in terms of AIC and BIC criteria, was found
to be strongly dependent on the structure selected for the variance–covariance matrices (see
Supplementary file 3). Initially, both models were defined with random effects on all parameters
and a diagonal matrix structure for the random effects, that is, individual random effects were
assumed independent. Different matrix structures were then compared and those with full matrices,
that is, in which random effects are correlated, were found to be the best.
For both adults and children, the AIC and BIC for the Ratio model were smaller than for the
Asymptotic model when baseline scaled CD4+ T-cell counts were estimated (Scenario 1). When the
baseline scaled CD4+ T-cell counts were used as a predictor (Scenario 2) this reversed. However, the
number of parameters estimated by the two models was different. For the Asymptotic model there
were three for scenario one vs two for scenario 2, a 33% change, and for the ratio model there five
for scenario one vs four for scenario 2, a 20% change (Table 2). Given the different numbers of
parameters, the Ratio performed well in comparison to the Asymptotic model.
In terms of parameter estimations, both models estimated baseline scaled CD4+ of similar magni-
tudes, for HIV-infected adults and children (Table 3 and Supplementary file 4 – Tables 1 and
2). The asymptotic model predicts a sharp increase of CD4+ counts, which rapidly reaches an asymp-
tote, while the ratio model predicts a sharp increase that is followed by a slower but still gradual
increase of scaled CD4+, up to more than 10 years after ART initiation (Figures 3 and 4).
We note that the parameter estimates obtained using a baseline CD4 scaling constant of 800
cells/mL for healthy adults were comparable to those obtained using age-dependent healthy adults
CD4 values (Supplementary file 2). Similarly, the estimates obtained using a baseline CD4 scaling
constant of 800 cells/ml for healthy adults were also comparable to those obtained without scaling
(i.e. using a scaling constant of 1 cell/mL) for all parameters except z0, whose estimate increased by
about 800-fold (Supplementary file 2) as expected.
Final ratio models
We found no major differences in the estimated fixed effects when adjusting the models for age and
sex only, versus adjusting for all our covariates. The minor differences between both fits were the
sizes of estimated parameters (Supplementary file 4 – Table 2), a few inconsistences in the effects
of age on particular parameters (adults and children) and sex effects on post-ART scaled carrying
capacity (adults only). Therefore, we only describe results for the models adjusted for all covariates.
These results are presented in Table 3. Note that a sample of individual fits is shown in Figure 3—
figure supplement 2 and Figure 4—figure supplement 2.
Population estimates/fixed effects
Both adults and children, on average, start ART with an impaired immune system. We found that
baseline scaled CD4+ T-cell count was 0.20 (95% CI: 0.18, 0.22) for adults and 0.74 (95% CI: 0.49,
1.00) for children (Scenario 1, Table 3).
The growth rates of CD4+ T-cell counts were more than tenfold higher in HIV infected versus
healthy individuals. We found that in adults, the growth rate for HIV-infected individuals was 0.49
cell counts per mL per day, while it was 0.02 for healthy individuals. In infected children, a growth
rate of 0.27 cell counts per mL per day was found, while it was much lower (0.01) in healthy children.
This means, for example, that an infected child starting ART with 100 cells will cross the 500 cells
threshold in 1470 days, whereas an infected adult with the same number of cells at ART initiation will
cross the threshold much faster, after about 816 days.
For HIV-infected individuals the scaled carrying capacity was higher than that of healthy individu-
als in both adults and children. We found that the scaled carrying capacity for HIV-infected adults
was 1.75, which is three times higher than that of healthy adults (0.49). We found that the scaled car-
rying capacity for HIV-infected children was above one (1.03). The scaled carrying capacity post-ART
of 1.75 in adults implied that an average 36.5 year old adult on ART would have to experience a
75% increase of their initial CD4+ T-cells to reach their ultimate CD4+ T-cell counts levels. For an
average 5-year-old child, this rebound needs to be much lower: 3% increase of their initial CD4+
T-cell counts, to reach normal ranges.
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Individual estimates and random effects
For both adults and children, the coefficient of variation for the random effects for all parameter esti-
mates was lower for the parameters of HIV-infected patients (k, r, and z0) and higher for the healthy
individual parameters (q and s). This is understandable given the lack of individual matching in the
data, that is, a person could not be HIV-infected and healthy simultaneously.
As can be seen in Table 4, the correlation between the random effects was similar in adults and
children, with the exception of the correlation between the scaled carrying capacity and growth rate
of CD4+ T-cells for healthy individuals, that was positive and strong (0.61) in adults, but weak and
negative ( 0.13) in children. The strongest correlation was between the scaled carrying capacity for
Table 3. Ratio model estimated parameters for children and adults.



















Variable Estimate (95% CI) Estimate (95% CI) Estimate (95% CI) Estimate (95% CI)
Scaled carrying capacity post ART (K) 1.03 (0.73,1.34) 1.13 (0.84, 1.41) 1.75 (1.59, 1.90) 1.69 (1.57, 1.80)
Sex, ref is male - -  0.06 ( 0.09,–0.03)*** -
Age, month 0.005 (0.004, 0.007)
***






 0.09 ( 0.12,–0.06)*** - -
Log viral load 0.06 (0.04, 0.08)*** 0.07 (0.05, 0.09)*** 0.069 (0.065, 0.073)*** 0.061 (0.058, 0.065)***
Suppress, ref is no - 0.001 ( 0.096, 0.092)** 0.11 (0.08, 0.14)*** 0.12 (0.10, 0.15)***
Scaled carrying capacity healthy individuals (Q) 0.68 (0.57, 0.78) 2.02 (1.59, 2.44) 0.49 (0.47, 0.52) 0.46 (0.36,0.56)
Sex, ref is male - -  0.55 ( 0.63,–0.47)***  0.54 ( 0.63,–0.46)***
Age, month  0.005 (0.003, 0.007)
***
- - 0.0002 ( 0.0001,
0.0006)
Scaled CD4+ T-cell count at ART initiation (z0) 0.74 (0.49, 1.00) - 0.20 (0.18, 0.22) -
Sex, ref is male - - 0.08 (0.05, 0.12)*** -





BMI 0.15 (0.11, 0.19)*** - - -





Rate of growth of CD4+ healthy individuals, cells per
L per day (s)
0.011 (0.007, 0.016) 0.002 (0.001, 0.003) 0.022 (0.016, 0.028) 0.02 (0.01,0.03)
Sex, ref is male - -  0.40 ( 0.53,–0.28)***  0.50 ( 0.62,–0.37)***
Age, month 0.008 (0.004, 0.017)
***




Rate of growth of CD4+ post ART, cells per L per
day (r)
0.27 (0.160,0.32) 0.17 (0.12, 0.21) 0.49 (0.39, 0.60) 0.79 (0.60, 0.97)
Sex, ref is male -  0.19 ( 0.33,–0.04)**





 0.07 ( 0.11,–0.03)*** - -
Log viral load 0.03 (0.00, 0.62)** 0.05 (0.03, 0.08)*** 0.11 (0.09, 0.13)*** 0.11 (0.09, 0.13)***
Suppress, ref is no  0.12 (- 0.27, 0.02)  0.15 ( 0.28,–0.03)***  0.57 ( 0.70,–0.44)***  0.62 ( 0.76,–0.47)***
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HIV-infected individuals and baseline scaled CD4+ T-cell counts, in both adults ( 0.67) and children
( 0.85).
Covariate estimates in children
We found that being 1 month older resulted in a decrease in baseline scaled CD4+ T-cell count of
 0.007 (95% CI:  0.009,  0.006). Similarly, being 1 month older was associated with a higher CD4+
T-cell growth rate in healthy children (0.008) and a significant decreasing effect on post-ART CD4+
T-cell growth rate ( 0.001). This means that, given a threshold of 200 CD4+ cell counts, younger
children will reach it earlier than older children that had a similar CD4+ T-cell count at baseline. Fur-
thermore, we found that age had a decreasing effect on the scaled carrying capacity of healthy chil-
dren ( 0.005).
Both scenarios show similar effects of baseline viral load on children’s parameters. We found that
one unit increase in baseline log viral load was associated with a  0.07 decrease in the baseline
scaled CD4+ T-cell count, and a +0.06 increase in the CD4+ T-cell scaled carrying capacity post-
ART. It also led to a +0.03 increase in the growth rate of CD4+ T-cells post-ART which indicates that
those with higher viral loads at ART initiation will reach a defined threshold faster than those with
lower viral loads, if they started with the same initial number of cells.
Baseline BMI z-score was associated with children’s baseline scaled CD4 T-cell count, post-ART
CD4+ T-cell scaled carrying capacity, and growth rate. One unit increase in baseline BMI z-score
resulted in an increase of +0.15 in baseline scaled CD4+ T-cell count, a decrease in the growth rate
of CD4+ T-cells post-ART ( 0.08) and in the post-ART scaled carrying capacity ( 0.12). An untreated
child with advanced HIV-disease is likely to have a low BMI z-score and will consequently have a
low scaled CD4+ T-cell count at ART initiation.
Covariate estimates in adults
In adults, being 1 month older was associated with an increase of +0.0006 (95% CI: 0.0004, 0.0008)
in baseline scaled CD4+ T-cell counts. We found no effect of age on post-ART CD4+ T-cell growth
rate, but it was associated with a decline in CD4+ T-cell growth rate in healthy adults ( 0.0012 per
month older). Our results show that being older was associated with a decrease in the scaled carry-
ing capacity in adults on ART ( 0.0007 per month older), though it had no effect on the scaled carry-
ing capacity of healthy adults.
Sex and baseline log viral load had an effect on CD4+ T-cell dynamics in adults. We found that
adult females started ART therapy at higher scaled CD4+ T-cell values compared to males (+ 0.08)
and one unit increase in baseline log viral load was associated with a decrease in
the baseline scaled CD4+ T-cell counts ( 0.08). We also observed a +0.07 increase in the CD4+
Table 4. Correlations of individual random effects.
Scenario 1 below the diagonal. Scenario 2 above.
K Q z0 s r
Scaled carrying capacity post ART – K Adults Scenario 2 0.40 - 0.48  0.28
Children Scenario 1  0.03 - 0.57 0.01
Scaled carrying capacity healthy ind – Q Adults 0.30 Scenario 2 - 0.37  0.41
Children 0.10 Scenario 1 -  0.47  0.24
Baseline scaled CD4+ T-cell count - z0 Adults  0.67 0.27 Scenario 2 - -
Children  0.85 0.38 Scenario 1 - -
Rate of growth of CD4+ healthy ind – s Adults 0.36 0.61  0.30 Scenario 2 0.15
Children 0.45  0.13  0.52 Scenario 1  0.22
Rate of growth of CD4+ post ART – r Adults  0.23  0.33  0.30 0.23 Scenario 2
Children  0.03  0.40  0.25 0.32 Scenario 1
In red: Opposite direction.
Underlined: Difference of correlation between children and adults.
Ujeneza et al. eLife 2021;10:e42390. DOI: https://doi.org/10.7554/eLife.42390 14 of 26
Research article Microbiology and Infectious Disease
T-cell scaled carrying capacity post-ART and a +0.11 increase in the growth rate of CD4+ T-cells
post-ART, per unit of increase in baseline log viral load.
Discussion
CD4+ T-cell count remains the main proxy used to evaluate the long-term effects of ART on the
immune system. Understanding its dynamics is crucial, to ensure that the best care is delivered to
HIV-infected patients. Although previous studies described CD4+ T-cell count dynamics in HIV-
treated patients, using non-mechanistic (Sempa et al., 2017) and mechanistic models (Lewis et al.,
2012; Means et al., 2016; Di Mascio et al., 2006), none provided a method that allows for direct
comparison with age-matched healthy controls. This study proposes a mechanistic model for the
immune system reconstitution, which relates CD4+ T-cells count of an individual on ART with that of
a healthy individual with similar characteristics. We demonstrate that CD4+ T-cell growth rates are
higher in HIV-treated patients than in healthy individuals and that age has opposite effects on CD4+
counts dynamics in HIV-treated children, compared to healthy children. This model was compared to
the asymptotic model, previously used to model CD4+ T-cell trajectories after ART initiation, under
two different scenarios: estimating baseline scaled CD4+ T-cell count (scenario 1) and using it as a
predictor (scenario 2). Moreover, this study is the first of its kind in evaluating large samples of chil-
dren and adults data in a comparative way.
Corbeau and Reynes, 2011 have described the three phases of CD4+ counts recovery in HIV-
treated patients: a sharp increase in the first 1–6 months, a still high increase up to 2 years, and a
slow gradual increase that goes on beyond 4 years of therapy. Our results show that though both
the ratio and asymptotic model predict similar scaled baseline CD4+ counts, only the ratio model is
able to reproduce these three phases of immune reconstitution. Thus, it is likely to be better in accu-
rately predicting the long-term behaviour of CD4+ T-cell counts trajectory. Furthermore, the ratio
model is derived directly from the logistic growth model which describes a known biological pro-
cess, and as such, CD4+ T-cells growth rate r is directly relatable to the average of the actual
increase of CD4+ T-cells per month over the observation period.
Baseline scaled CD4+ T-cell counts (z0)
Fitting our model to the data demonstrated that larger values of baseline scaled CD4+ T-cell counts
are associated with larger values of scaled CD4+ T-cell counts at any subsequent time. This is the
consequence of equation 4, which is in line with the findings of prior studies in which higher baseline
CD4+ T-cell counts were associated with a higher final or plateauing value for CD4+ T-cell counts
(Moore and Keruly, 2007). Similarly, patients with very low baseline CD4+ T-cell counts, <350 cells/
mL, often fail to reach normal values even after long durations of therapy (Nakanjako, 2016;
Swiss HIV Cohort Study et al., 2005; Moore and Keruly, 2007; Kelley et al., 2009). We also found
that the scaled carrying capacity of CD4+ T-cells in HIV-infected individuals was negatively corre-
lated with the baseline scaled CD4+ T-cell counts in both adults and children, respectively,  0.64
and  0.81. This seems reasonable in that the closer an individual is to their normal or optimal CD4+
T-cell value at ART initiation, the less cell population expansion is required to reach normal levels.
Scaled carrying capacity of CD4+ T-cells for HIV-infected and healthy
individuals
Our parameter estimates demonstrated that the scaled cellular carrying capacity was higher in indi-
viduals on ART than in those who were healthy. In both HIV-infected adults and children the scaled
carrying capacity post-ART was greater than 1, meaning that baseline CD4+ T-cell counts were lower
than their corresponding long-term homeostatic optimum. That is, individual CD4+ T-cell counts had
to grow to reach normal levels. This is consistent with the notion that an impaired immune system
usually experiences repair following treatment initiation.
In contrast, the scaled capacity for healthy adults and children were both lower than unity. In chil-
dren the value was 0.68, which is consistent with a mechanistic understanding of the dynamics of
healthy CD4+ T-cell counts in early life. In particular, there is an increase until the age of approxi-
mately 1 year and then a decrease thereafter (Bains et al., 2009). Total blood and body volume
increase throughout childhood associated with the shrinkage of the thymus, which is accompanied
by a reduction of naı̈ve T-cell production (Hapuarachchi et al., 2013; Hazenberg et al., 2004). In
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combination, this results in decreasing CD4+ T-cell counts per volume with age. In healthy adults,
we found a scaled carrying capacity of 0.49, suggesting a decreasing CD4+ T-cell trend with age.
This is in agreement with other studies from elsewhere which found that CD4+ T-cell counts
decreased from young adulthood to middle age (Lugada et al., 2004; Zeh et al., 2011). However,
one study in healthy South African adults has described CD4+ T-cell counts increasing slightly until
the age of 64 years old (Malaza et al., 2013).
Post-ART CD4+ T-cell count growth rate depends on scaled baseline
CD4+ T-cell counts
We found that post-ART CD4+ T-cell growth rate depends inversely on the cell count at treatment
initiation, that is, they are negatively correlated (Table 4). This implies that the higher the scaled
CD4+ T-cell counts of an individual at ART initiation, that is, the closer it is to its healthy/normal true
value, the lower the rate of recovery will be. This is reasonable given a decrease in the need to
achieve normal levels and is in agreement with the findings of prior studies (Lawn et al., 2006;
Sachsenberg et al., 1998).
Post-ART CD4+ T-cell growth rates in HIV-infected versus healthy
individuals
We found that CD4+ T-cell growth rates were higher in individuals on ART than in healthy individu-
als. This agrees with prior studies in which cell growth rates in adults on ART were estimated to be
sixfold to tenfold greater than in healthy adults (Sachsenberg et al., 1998; Hazenberg et al., 2000).
This is understandable bearing in mind the immune system’s effort after treatment initiation to re-fill
the void of peripheral CD4+ T-cells destroyed during HIV infection. Biological studies have
described this as an initial redistribution of memory T-cells from the lymph nodes into the blood
stream, followed by homeostatic proliferation and production of naı̈ve cells by the thymus
(Tsukamoto et al., 2009; Autran, 1999). Thus, given that HIV-infected individuals have much lower
CD4+ T-cell counts they require higher CD4+ T-cell growth rates than healthy individuals. This
behaviour was captured by our model.
Interestingly, the differences in our estimates for CD4+ T-cell growth rate in healthy individuals
versus patients on ART were slightly lower than those found elsewhere (Sachsenberg et al., 1998).
This may be due to: the differences in the total time of follow-up of our patients, selection bias in
the original population data, differences in the demographics of the populations studied, the types
of treatments administered, and changes in the WHO guidelines for ART initiation over time. The
WHO guidelines for minimal CD4+ T-cell counts at initiation changed from 200, to 350, to 500 and
later to initiation at diagnosis. Thus, post-ART CD4+ T-cell growth rate in HIV-infected individual
might be smaller now than it may have been on average in the past, as CD4+ T-cell counts at ART
initiation are now higher.
The effects of age
Baseline scaled CD4+ T-cell count was lower in adults compared to children (0.2 vs 0.8), that is,
adults started treatment when their immune systems were more compromised compared to chil-
dren. This could be due to the fact that children (<17 years old) are more likely vertically infected
and, thus, they are more likely to be diagnosed early, owing to early testing and follow-up in the
South African program for prevention of mother-to-child transmission. Adults, on the other hand,
might be infected for an extended period and are consequently more likely to be more highly
immune-compromised prior to diagnosis, compared to children.
We found that older age is associated with a lower value of baseline scaled CD4+ T-cell count in
children and a higher value in adults. Vertical HIV- infection and an extended duration without treat-
ment may lead to greater immune compromise in older children. In contrast, higher baseline scaled
CD4+ T-cell counts in older adults suggest that they may have been more health conscious than
younger adults (Prohaska et al., 1985), that is, younger adults tend to seek treatment later than
older adults.
Such findings might also be explained by the negative correlation between post-ART CD4+ T-cell
growth rates and baseline CD4+ T-cell counts: younger adults have a higher growth rate as they
start at a lower CD4+ T-cell count value (Cornell et al., 2012). Thus, their CD4+ T-cell rebound value
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may be higher than that of older adults over a similar period of time (Means et al., 2016;
International epidemiological Database to Evaluate AIDS (IeDEA) West Africa Collaboration
et al., 2012). Our results make no inferences regarding the period an individual takes to reach their
normal CD4+ T-cell count value.
Sex effects
We found that adult females have lower post-ART scaled carrying capacities than men, meaning
they need a lower CD4+ T-cell count rebound to reach normality. This suggests that female adults
tend to initiate treatment earlier than men (Cornell and Myer, 2013). This was also validated by the
fact that baseline scaled CD4+ T-cell counts were higher in females than in males. A prior study has
also found that women tend to have higher plateauing CD4+ T-cell counts than men (Means et al.,
2016). In our study, women had lower rates of recovery than males which also supports our finding
that higher baseline scaled CD4+ T-cell count is associated with a lower CD4+ T-cell growth rate. As
they have higher CD4+ T-cell counts at ART initiation, and given the inverse correlation between the
post-ART CD4+ T-cell growth rate and baseline scaled CD4+ T-cell count, women demonstrate
lower growth rates.
Previous studies have found that adult males and females spend a similar time on therapy before
reaching their rebound set-point CD4+ T-cell count (EuroSIDA group et al., 2003; Patterson et al.,
2007). We do not consider this a contradiction of our results as an individual with a higher baseline
CD4+ T-cell count will have a lower cell growth rate compared to an individual that started ART with
a low CD4+ count. Thus, after an equivalent period following ART initiation similar increases in CD4
+ T-cell counts may have occurred. We believe that the diverging opinions regarding the effects of
sex on immune outcomes in adults post-ART initiation might be explained by variations in the defini-
tions of ‘immunological outcomes’ by different authors and variations in analyses conducted.
This study has strengths and limitations. To ensure that patients had sufficient data to enable
parameterization of the model, only subsets of the full data set were used in the analysis. This pre-
vented over-fitting, but it might have introduced selection bias. However, with the exception of the
percentage of people that suppressed viral load within 12 months of starting ART (Table 1), compar-
ison of the summary statistics of the subset versus the full data set demonstrated that they were sim-
ilar. Further, the results obtained from adjusting and not adjusting the model parameters with the
variable, viral load suppression within 12 months, were also in agreement (see Supplementary file
4). We consequently believe that the subset used was representative of the full data set. Our model
does not distinguish between naı̈ve and memory sub-types of CD4+ T-cells. Prior studies have
shown that these have different dynamics (Di Mascio et al., 2006; Bajaria et al., 2002). However, in
routine HIV monitoring, for which we had data, the different subtypes are not measured. As ART
treatment is for life, separating analyses for children from that for adults does not account for chil-
dren growing into adulthood. Future studies might express the scaled carrying capacity as a function
of age rather than as a variable parameter. Ignoring the thymus’s contribution to CD4+ T-cell recov-
ery, particularly in the earlier years of life, might have resulted in an overestimation of r and s
parameters which are aggregate growth rates. Lastly, scaling the CD4+ T-cell counts of adults by a
single average healthy CD4+ count value for adults might have introduced bias in the estimates of
the scaled carrying capacity of healthy adults, due to variations of CD4+ T-cell counts across differ-
ent age and demographic groups.
Our study does provide insight into the effect of ageing on immune system dynamics in adults
and children on ART compared to healthy individuals. The ratio model provides a more accurate
estimation of CD4+ counts reconstitution than the asymptotic model as well as the ability to com-
pare different immune system outcomes, for both healthy and HIV-treated individuals. Using scaled
CD4+ T-cell counts allows for the evaluation of CD4+ counts trajectories, which is not possible with
unscaled CD4+ T-cell counts. We found large variations in CD4+ T-cell growth rates and scaled car-
rying capacities between individuals, highlighting the need to evaluate ART outcomes on an individ-
ual level. This calls for improved patient monitoring strategies. The strong inverse correlation
between baseline scaled CD4+ T-cell count and the scaled carrying capacity emphasizes the impor-
tance of early ART initiation, regardless of age or state of disease progression. We found that post-
ART CD4+ T-cell growth rate is not associated with a patient’s age, but it is associated with higher
baseline viral load. With the expansion of an aging population on ART, understanding long-term
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effects of the treatment on the immune system is critical to ensure that the best care is delivered to
HIV-infected patients.
Acknowledgements
The authors gratefully acknowledge the support from Dr Joanna Lewis in the initial conceptualization
of the study and the Centre for High Performance computing in Cape Town (http://www.chpc.ac.za)
for providing part of the computational facilities.
Additional information
Funding
Funder Grant reference number Author
Schlumberger Stichting Fund,
under the context of the Future
Fellowship Program
Eva Liliane Ujeneza
South African Department of
Science and Technology and
the National Research Foun-
dation’s Center of Excellence
for Modelling and Analysis of
Epidemiological Data
Eva Liliane Ujeneza
National Institute Of Allergy
And Infectious Diseases of the
National Institutes of Health
U01AI069924 Mary-Ann Davies
The funders had no role in study design, data collection and interpretation, or the
decision to submit the work for publication.
Author contributions
Eva Liliane Ujeneza, Conceptualization, Data curation, Software, Formal analysis, Funding acquisi-
tion, Validation, Investigation, Visualization, Methodology; Wilfred Ndifon, Software, Formal analysis,
Supervision, Validation, Investigation, Methodology; Shobna Sawry, Geoffrey Fatti, Julien Riou, Data
curation; Mary-Ann Davies, Conceptualization, Data curation, Project administration; Martin Nieu-
woudt, Conceptualization, Resources, Data curation, Supervision, Funding acquisition, Validation,
Investigation, Methodology, Project administration
Author ORCIDs
Eva Liliane Ujeneza https://orcid.org/0000-0002-5760-4847
Geoffrey Fatti http://orcid.org/0000-0002-6467-662X
Ethics
Human subjects: This study was approved as part of the IeDEA Southern African collaboration’s pro-
tocol, by the Human Research Ethics Committee of the University of Cape Town, with a reference
number N1810119 RECIP UCT 084/2006. Informed consent was obtained from all participants by
the clinics collecting the data according to IeDEA protocols.





. Supplementary file 1. Range of the ratio model parameters.
Ujeneza et al. eLife 2021;10:e42390. DOI: https://doi.org/10.7554/eLife.42390 18 of 26
Research article Microbiology and Infectious Disease
. Supplementary file 2. Comparison of parameter estimates for adults, obtained using different fit-
ting scenarios.
. Supplementary file 3. Evaluation of the variance–covariance matrix for the ratio and asymptotic
models.
. Supplementary file 4. Additional estimated parameters.
. Transparent reporting form
Data availability
Data used are from the International Epidemiologic Databases to Evaluate AIDS Southern Africa col-
laboration. They maintain a database of routinely collected data from various clinics, mostly located
in South Africa. We recommend that interested readers contact Dr Morna Cornell, Project Manager
IeDEA-SA in Cape Town (morna.cornell@uct.ac.za) to establish a data-sharing agreement. A research
proposal highlighting how the data will be used is required. Source data for figures and figure sup-
plements are provided, and the source code is available at https://github.com/EvaLiliane/RM_Code_
eLife copy archived at https://archive.softwareheritage.org/swh:1:rev:
624ff31c5fc969885f29b7291ee06886d24c64f7/.
References
Abuye C, Tsegaye A, West CE, Versloot P, Sanders EJ, Wolday D, Hamann D, De Wit TF, Fontanet AL. 2005.
Determinants of CD4 counts among HIV-negative ethiopians: role of body mass index, gender, cigarette
smoking, khat (Catha edulis) chewing, and possibly altitude? Journal of Clinical Immunology 25:127–133.
DOI: https://doi.org/10.1007/s10875-005-2818-y, PMID: 15821889
ANRS 1215/90 Study Group, De Beaudrap P, Etard JF, Diouf A, Ndiaye I, Guèye NF, Guèye PM, Sow PS,
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Appendix 1
A1: Simulated references CD4+ T-cells values per age, for healthy
children
Cross-sectional CD4+ T-cell counts data of 381 healthy children were collected as part of a study
that sought to evaluate the use of international paediatric reference intervals by NHLS for South Afri-
can populations (Lawrie et al., 2015). The study was conducted at a child wellness clinic, in Wes-
bank, a semi-informal settlement located in Cape Town. Healthiness was defined as not being on
any prescribed medication, no chronic illness, a full clinical history, and attendance of the child to
the clinic, with his/her biological mother. These children had a median age of 18.9 months IQR (6.5,
45.6) and a median CD4+ T-cell counts of 2007 cells/mL IQR (1433, 2749).
We simulated age-dependent normal CD4+ counts for healthy children, using a single exponen-
tial model as suggested in previous (unpublished) work. We model healthy CD4+ counts of a healthy
child at age a as follow:
f að Þ ¼ C0 þ C1exp  C2að Þ,
where the constants C0 and C1 (unit: cells per mL) give an indication of the CD4+ count of a child
at birth, and C2 indicates the rate of decline of CD4+ counts (unit: cells per mL per month), thereaf-
ter. We used generalized nonlinear least squares method to estimate the model’s parameters. We
found that C0; C1 , and C2 were equal to 1070, 2.174, and 0.031 respectively. Using these values, we
simulated CD4+ counts references values for each month of age, from birth until 17 years. As an
indication, a sample of the simulated values are shown in the table below. The graph (see Appen-
dix 1—figure 1) shows the raw data with the simulated references values as a red line.
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Appendix 1—figure 1. Plot of the simulated reference values for children. The dots represent the
cross-sectional data for healthy children. The fitted red line shows the age-dependent reference
values used in the scaling of CD4+ counts of HIV-infected children.
The online version of this article includes the following source data is available for figure 1:
Appendix 1—figure 1—source data 1. Simulated reference values for children.
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A2: Age and sex-dependent CD4+ T-cell counts reference values for
healthy adults
In the study, we scaled all adults CD4+ counts by a single constant value, matching the studies
below.
Appendix 1—table 2. Studies that evaluated normal CD4+ T-cells references ranges normal ranges




Country Age-related commentsMale Female









Median age for women is 35 years vs 23
years for men. CD4+ count increase
slightly with age till 64 years old









Average age of 41 years for all




Tanzania Mean age for women is 30.9 years vs 35.2
for men








Uganda Decrease with age from birth to 18 years.
All aged 24 were lumped together
Institute of Human Virology/Plateau
State Specialist Hospital AIDS
Prevention in Nigeria Study Team et al.,





Nigeria No age effect found






Nigeria Decreasing with age
We also fitted cubic splines to age-group published median CD4+ counts data (Malaza et al.,
2013), for men and women separately. We then simulated age-dependent reference values as
shown in the graph below (Appendix 1—figure 2). We found no difference between our initial
results and those obtained from scaling data of HIV-infected adults by age and sex-dependent refer-
ence values.
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Appendix 1—figure 2. Plot of the simulated reference values for adults. The points represent the
published median values. The red line shows the CD4+ count for women, blue line is for men. CD4+
reference values were simulated yearly, for ages ranging between 17 and 95.
The online version of this article includes the following source data is available for figure 2:
Appendix 1—figure 2—source data 1. Simulated reference values for adults.
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